Skip to main content
NCBI home page
Tobacco Control logoLink to Tobacco Control
. 2004 Dec;13(4):422–428. doi: 10.1136/tc.2003.007070

Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers

J O'Loughlin 1, G Paradis 1, W Kim 1, J DiFranza 1, G Meshefedjian 1, E McMillan-Davey 1, S Wong 1, J Hanley 1, R Tyndale 1
PMCID: PMC1747926  PMID: 15564629

Abstract

Objective: Case control studies in adults suggest that defective alleles in the gene that codes for the hepatic cytochrome P450 2A6 (CYP2A6) protect against nicotine dependence (ND) and higher levels of cigarette consumption. These two hypotheses were tested in young adolescents.

Design: Self reports of tobacco use and ND symptoms were collected every 3–4 months in a prospective study of 1293 grade 7 students from a convenience sample of 10 schools.

Subjects: 281 smokers with genetic data were analysed; those who were not already tobacco dependent and who had inhaled (n = 228) were followed 29.9 months on average, until they became dependent or were censored.

Main outcome measures: The association between metabolic activity, represented by CYP2A6 genotype, and conversion to dependence was analysed using Cox's proportional hazards model.

Results: During follow up 67 subjects (29.4%) became dependent. Relative to CYP2A6*1/*1, having 1–2 copies of the inactive CYP2A6*2 or *4 variant was a strong risk factor for developing dependence (hazard ratio 2.8, 95% confidence 1.3 to 6.3). Subjects with 1–2 partially inactive CYP2A6*9 or *12 variants were not at increased risk. Mean past-week cigarette consumption at the end of follow up (controlling for age, sex, and number of months since first inhalation) among dependent subjects was 29.1 among normal inactivators, compared to 17.2, and 12.7 among slower (1–2 copies of *9 or *12), and slowest (1–2 copies of *2 or *4) inactivators, respectively (p = 0.09).

Conclusion: Adolescents with 1–2 copies of CYP2A6*2 or *4 are at substantially increased risk of becoming dependent but smoke less once dependent. Genetic risk for ND may need to be considered in the conceptualisation of tobacco control programmes for adolescents.

Full Text

The Full Text of this article is available as a PDF (196.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abreu-Villaça Yael, Seidler Frederic J., Qiao Dan, Tate Charlotte A., Cousins Mandy M., Thillai Indira, Slotkin Theodore A. Short-term adolescent nicotine exposure has immediate and persistent effects on cholinergic systems: critical periods, patterns of exposure, dose thresholds. Neuropsychopharmacology. 2003 Nov;28(11):1935–1949. doi: 10.1038/sj.npp.1300221. [DOI] [PubMed] [Google Scholar]
  2. Ando Masahiko, Hamajima Nobuyuki, Ariyoshi Noritaka, Kamataki Tetsuya, Matsuo Keitaro, Ohno Yoshiyuki. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. J Epidemiol. 2003 May;13(3):176–181. doi: 10.2188/jea.13.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benowitz N. L., Jacob P., 3rd Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther. 1994 Nov;56(5):483–493. doi: 10.1038/clpt.1994.169. [DOI] [PubMed] [Google Scholar]
  4. Breslau N., Johnson E. O. Predicting smoking cessation and major depression in nicotine-dependent smokers. Am J Public Health. 2000 Jul;90(7):1122–1127. doi: 10.2105/ajph.90.7.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Centers for Disease Control and Prevention (CDC) Selected cigarette smoking initiation and quitting behaviors among high school students--United States, 1997. MMWR Morb Mortal Wkly Rep. 1998 May 22;47(19):386–389. [PubMed] [Google Scholar]
  6. Dempsey D., Jacob P., 3rd, Benowitz N. L. Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther. 2000 May;67(5):458–465. doi: 10.1067/mcp.2000.106129. [DOI] [PubMed] [Google Scholar]
  7. DiFranza J. R., Savageau J. A., Rigotti N. A., Fletcher K., Ockene J. K., McNeill A. D., Coleman M., Wood C. Development of symptoms of tobacco dependence in youths: 30 month follow up data from the DANDY study. Tob Control. 2002 Sep;11(3):228–235. doi: 10.1136/tc.11.3.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flynn B. S., Worden J. K., Secker-Walker R. H., Badger G. J., Geller B. M., Costanza M. C. Prevention of cigarette smoking through mass media intervention and school programs. Am J Public Health. 1992 Jun;82(6):827–834. doi: 10.2105/ajph.82.6.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gourlay S. G., Benowitz N. L. The benefits of stopping smoking and the role of nicotine replacement therapy in older patients. Drugs Aging. 1996 Jul;9(1):8–23. doi: 10.2165/00002512-199609010-00002. [DOI] [PubMed] [Google Scholar]
  10. Gu D. F., Hinks L. J., Morton N. E., Day I. N. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet. 2000 Sep;64(Pt 5):383–390. doi: 10.1046/j.1469-1809.2000.6450383.x. [DOI] [PubMed] [Google Scholar]
  11. Hymowitz N., Cummings K. M., Hyland A., Lynn W. R., Pechacek T. F., Hartwell T. D. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6 (Suppl 2):S57–S62. doi: 10.1136/tc.6.suppl_2.s57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krul C., Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):27–34. doi: 10.1016/s0378-4347(98)00016-4. [DOI] [PubMed] [Google Scholar]
  13. Leong J. W., Dore N. D., Shelley K., Holt E. J., Laing I. A., Palmer L. J., LeSouef P. N. The elimination half-life of urinary cotinine in children of tobacco-smoking mothers. Pulm Pharmacol Ther. 1998;11(4):287–290. doi: 10.1006/pupt.1998.0153. [DOI] [PubMed] [Google Scholar]
  14. Lerman Caryn, Niaura Raymond. Applying genetic approaches to the treatment of nicotine dependence. Oncogene. 2002 Oct 21;21(48):7412–7420. doi: 10.1038/sj.onc.1205801. [DOI] [PubMed] [Google Scholar]
  15. Loriot M. A., Rebuissou S., Oscarson M., Cenée S., Miyamoto M., Ariyoshi N., Kamataki T., Hémon D., Beaune P., Stücker I. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics. 2001 Feb;11(1):39–44. doi: 10.1097/00008571-200102000-00005. [DOI] [PubMed] [Google Scholar]
  16. Messina E. S., Tyndale R. F., Sellers E. M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997 Sep;282(3):1608–1614. [PubMed] [Google Scholar]
  17. Minematsu N., Nakamura H., Iwata M., Tateno H., Nakajima T., Takahashi S., Fujishima S., Yamaguchi K. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax. 2003 Jul;58(7):623–628. doi: 10.1136/thorax.58.7.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. O'Loughlin J., DiFranza J., Tarasuk J., Meshefedjian G., McMillan-Davey E., Paradis G., Tyndale R. F., Clarke P., Hanley J. Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators. Tob Control. 2002 Dec;11(4):354–360. doi: 10.1136/tc.11.4.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. O'Loughlin Jennifer, DiFranza Joseph, Tyndale Rachel F., Meshefedjian Garbis, McMillan-Davey Elizabeth, Clarke Paul B. S., Hanley James, Paradis Gilles. Nicotine-dependence symptoms are associated with smoking frequency in adolescents. Am J Prev Med. 2003 Oct;25(3):219–225. doi: 10.1016/s0749-3797(03)00198-3. [DOI] [PubMed] [Google Scholar]
  20. Oscarson Mikael, McLellan Roman A., Asp Vendela, Ledesma MariCarmen, Bernal Ruiz Maria Luisa, Sinues Blanca, Rautio Arja, Ingelman-Sundberg Magnus. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat. 2002 Oct;20(4):275–283. doi: 10.1002/humu.10126. [DOI] [PubMed] [Google Scholar]
  21. Pasanen M., Rannala Z., Tooming A., Sotaniemi E. A., Pelkonen O., Rautio A. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology. 1997 Dec 5;123(3):177–184. doi: 10.1016/s0300-483x(97)00119-4. [DOI] [PubMed] [Google Scholar]
  22. Pianezza M. L., Sellers E. M., Tyndale R. F. Nicotine metabolism defect reduces smoking. Nature. 1998 Jun 25;393(6687):750–750. doi: 10.1038/31623. [DOI] [PubMed] [Google Scholar]
  23. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E. M., Tyndale R. F. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol. 2000 Oct;58(4):747–755. doi: 10.1124/mol.58.4.747. [DOI] [PubMed] [Google Scholar]
  24. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology (Berl) 1999 Jul;145(1):1–20. doi: 10.1007/s002130051027. [DOI] [PubMed] [Google Scholar]
  25. Tiihonen J., Pesonen U., Kauhanen J., Koulu M., Hallikainen T., Leskinen L., Salonen J. T. CYP2A6 genotype and smoking. Mol Psychiatry. 2000 Jul;5(4):347–348. doi: 10.1038/sj.mp.4000710. [DOI] [PubMed] [Google Scholar]
  26. Tyndale Rachel F. Genetics of alcohol and tobacco use in humans. Ann Med. 2003;35(2):94–121. doi: 10.1080/07853890310010014. [DOI] [PubMed] [Google Scholar]
  27. Tyndale Rachel F., Sellers Edward M. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit. 2002 Feb;24(1):163–171. doi: 10.1097/00007691-200202000-00026. [DOI] [PubMed] [Google Scholar]
  28. Willers S., Skarping G., Dalene M., Skerfving S. Urinary cotinine in children and adults during and after semiexperimental exposure to environmental tobacco smoke. Arch Environ Health. 1995 Mar-Apr;50(2):130–138. doi: 10.1080/00039896.1995.9940890. [DOI] [PubMed] [Google Scholar]
  29. Xu Chun, Goodz Shari, Sellers Edward M., Tyndale Rachel F. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1245–1256. doi: 10.1016/s0169-409x(02)00065-0. [DOI] [PubMed] [Google Scholar]
  30. Yoshida Ryoko, Nakajima Miki, Nishimura Kiyoko, Tokudome Shogo, Kwon Jun-Tack, Yokoi Tsuyoshi. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther. 2003 Jul;74(1):69–76. doi: 10.1016/S0009-9236(03)00090-0. [DOI] [PubMed] [Google Scholar]
  31. Zhang X., Amemo K., Ameno S., Iwahashi K., Kinoshita H., Kubota T., Mostofa J., Ijiri I. Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2001 Oct;36(5):486–490. [PubMed] [Google Scholar]

Articles from Tobacco Control are provided here courtesy of BMJ Publishing Group

RESOURCES